At the forefront of cardiac care, we here at Abbott are excited to announce that our Assert-IQ™ Insertable Cardiac Monitor (ICM) has been cleared by the FDA.
Through this device, we have transformed the detection and management of arrhythmias and have engineered a new experience that provides the best diagnostic solution for your staff and patients. This solution is focused on the areas most meaningful for cardiac monitoring:
See how the Assert-IQ ICM is designed to outperform and built to outlast:
The Assert-IQ ICM’s advanced algorithms reduce false detections by 98.7% for AF and Pause while maintaining 97.7% of true EGMs.1,4,5 Our AF algorithm reduces data burden by 21% compared to the latest version of LINQ II‡*,1-3 and utilizes a five-step AF detection discriminator that focuses on R-R interval patterns and P-Waves in EGMs to verify if an event is true or false.
As the longest lasting Bluetooth®-enabled ICM† device, it operates at full functionality beyond six years. Plus, it features remote programmability capabilities that make it easier to adjust parameters, saving valuable time for you and your patients. Here’s how it works:
Advanced Bluetooth® technology checks in every 20 seconds with the connected device to capture, encrypt and transfer patient data to the Merlin.net™ Patient Care Network (PCN) via a connected mobile device with the myMerlin™ Mobile App. A reprogramming request can be initiated and transmitted to a patient through the app quickly and easily – all without the need for an office visit.
To meet the evolving needs of patients using remote monitoring with an ICM, we are offering two battery life options:
The first is a minimum of three years. This may be preferred for more traditional monitoring purposes, such as diagnosing syncope, palpitations or detecting AF in cryptogenic stroke patients. The second is a minimum of six years. This may be preferred for longer-term monitoring of patients, such as those undergoing therapy and at risk of additional arrhythmias
Additional IQ Insights are another exciting new feature of our Assert-IQ™ ICM. These sensors help you make data-driven decisions faster and more confidently. Some of the diagnostics the new sensors capture include:
Leading PVC detection algorithms offers the ability to capture consecutive events, including couplets and triplets.6
An ICM first.5, 7-11
Assess new patient factors to help adjudicate episodes.
Assess AFib Burden, PVCs, Activity Trends, and MORE!
Assert-IQ ICM provides the best diagnostic solutions for your staff and for your patients who require long-term monitoring. Learn more by visiting the Assert-IQ ICM website and reading this press release.
*As of 12.31.22, LINQ II‡ with AccuRhythm‡ AI. EGM burden comparison is based on two independent, random, real-world data sets. Patient characteristics and device programming may differ.
References:
†As of 12.31.22. Reveal LINQ‡ User Manual, LINQ II‡ User Manual, Lux Dx‡ User Manual, Biomonitor III‡ User Manual, Biomonitor IIIm‡ User Manual
MAT-2305989 v1.0 | Item is approved for U.S. use only
